Skip to content

Study · Animal study (in vivo) · rat · 2017

6 results

Demonstration of therapeutic window of Cerebrolysin in embolic stroke: A prospective, randomized, blinded, and placebo-controlled study.

Zhang L, Chopp M, Lu M, Zhang T, Li C, Winter S, Brandstaetter H, Doppler E, Meier D, Pabla P, Zhang ZG

International journal of stroke : official journal of the International Stroke Society6 Apr 2017Cited by 6 (Europe PMC)

PMID28382851 (opens in a new tab)DOI10.1177/1747493017702665 (opens in a new tab)PepBankPUB-28382851
Publisher pagePubMedAsk about this study
Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In rats with embolic stroke, infarct volume did not differ among Cerebrolysin and saline groups.

    In plain wordsIn rats with stroke, brain infarct volume did not differ among Cerebrolysin and saline groups.

    Peptide
    Cerebrolysin
    Outcome
    No significant changeInfarct volume
    Study

    ratn = 100

    Male Wistar rats with embolic middle cerebral artery occlusion
    Comparator
    Saline
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    Dose not stated · 10 consecutive daysAs given in this study (rat).

    Source sentences

    Summary
    There were no differences on infarct volume and mortality rate among groups.
    2 context sentences
    Summary · context
    Here, we conduct a prospective, randomized, placebo-controlled, blinded study to examine the therapeutic window of Cerebrolysin treatment of rats subjected to embolic stroke.
    Summary · context
    Animals were randomized to receive saline or Cerebrolysin daily for 10 consecutive days starting 4, 24, 48, and 72 h after middle cerebral artery occlusion.
  2. 02AnimalAnimal study (in vivo)Safety outcome

    In rats with embolic stroke, mortality did not differ among Cerebrolysin and saline groups.

    In plain wordsIn rats with stroke, death rates did not differ among Cerebrolysin and saline groups.

    Peptide
    Cerebrolysin
    Outcome
    No significant changeMortality
    Study

    ratn = 100

    Male Wistar rats with embolic middle cerebral artery occlusion
    Comparator
    Saline
    Outcome group
    Mortality · Whole body
    Studied dose
    Dose not stated · 10 consecutive daysAs given in this study (rat).

    Source sentences

    Summary
    There were no differences on infarct volume and mortality rate among groups.
    2 context sentences
    Summary · context
    Here, we conduct a prospective, randomized, placebo-controlled, blinded study to examine the therapeutic window of Cerebrolysin treatment of rats subjected to embolic stroke.
    Summary · context
    Animals were randomized to receive saline or Cerebrolysin daily for 10 consecutive days starting 4, 24, 48, and 72 h after middle cerebral artery occlusion.
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    In rats with embolic stroke, Cerebrolysin initiated at 4 h improved functional outcome versus saline.

    In plain wordsIn rats with stroke, Cerebrolysin started at 4 h improved function compared with saline.

    Peptide
    Cerebrolysin
    Outcome
    IncreaseFunctional outcome with treatment at 4 h
    Study

    ratn: not reported in source

    Male Wistar rats with embolic middle cerebral artery occlusion
    Comparator
    Saline
    Outcome group
    Exercise and physical function · Nervous system and cognition
    Studied dose
    Dose not stated · 10 consecutive daysAs given in this study (rat).

    Measurements

    Mean difference
    −11.6
    4 h

    Source sentences

    Summary
    Results Cerebrolysin treatment initiated within 48 h after middle cerebral artery occlusion onset significantly improved functional outcome; mean differences and 95% confidence interval were -11.6 (-17.7, -5.4) at 4 h, -7.1 (-13.5, -0.8) at 24 h, -8.4 (-14.2, -8.6) at 48 h, and -4.9 (-11.4, 1.5) at 72 h.
    2 context sentences
    Summary · context
    Here, we conduct a prospective, randomized, placebo-controlled, blinded study to examine the therapeutic window of Cerebrolysin treatment of rats subjected to embolic stroke.
    Summary · context
    Animals were randomized to receive saline or Cerebrolysin daily for 10 consecutive days starting 4, 24, 48, and 72 h after middle cerebral artery occlusion.
  4. 04AnimalAnimal study (in vivo)Efficacy outcome

    In rats with embolic stroke, Cerebrolysin initiated at 24 h improved functional outcome versus saline.

    In plain wordsIn rats with stroke, Cerebrolysin started at 24 h improved function compared with saline.

    Peptide
    Cerebrolysin
    Outcome
    IncreaseFunctional outcome with treatment at 24 h
    Study

    ratn: not reported in source

    Male Wistar rats with embolic middle cerebral artery occlusion
    Comparator
    Saline
    Outcome group
    Exercise and physical function · Nervous system and cognition
    Studied dose
    Dose not stated · 10 consecutive daysAs given in this study (rat).

    Measurements

    Mean difference
    −7.1
    24 h

    Source sentences

    Summary
    Results Cerebrolysin treatment initiated within 48 h after middle cerebral artery occlusion onset significantly improved functional outcome; mean differences and 95% confidence interval were -11.6 (-17.7, -5.4) at 4 h, -7.1 (-13.5, -0.8) at 24 h, -8.4 (-14.2, -8.6) at 48 h, and -4.9 (-11.4, 1.5) at 72 h.
    2 context sentences
    Summary · context
    Here, we conduct a prospective, randomized, placebo-controlled, blinded study to examine the therapeutic window of Cerebrolysin treatment of rats subjected to embolic stroke.
    Summary · context
    Animals were randomized to receive saline or Cerebrolysin daily for 10 consecutive days starting 4, 24, 48, and 72 h after middle cerebral artery occlusion.
  5. 05AnimalAnimal study (in vivo)Efficacy outcome

    In rats with embolic stroke, Cerebrolysin initiated at 48 h improved functional outcome versus saline.

    In plain wordsIn rats with stroke, Cerebrolysin started at 48 h improved function compared with saline.

    Peptide
    Cerebrolysin
    Outcome
    IncreaseFunctional outcome with treatment at 48 h
    Study

    ratn: not reported in source

    Male Wistar rats with embolic middle cerebral artery occlusion
    Comparator
    Saline
    Outcome group
    Exercise and physical function · Nervous system and cognition
    Studied dose
    Dose not stated · 10 consecutive daysAs given in this study (rat).

    Measurements

    Mean difference
    −8.4
    48 h

    Source sentences

    Summary
    Results Cerebrolysin treatment initiated within 48 h after middle cerebral artery occlusion onset significantly improved functional outcome; mean differences and 95% confidence interval were -11.6 (-17.7, -5.4) at 4 h, -7.1 (-13.5, -0.8) at 24 h, -8.4 (-14.2, -8.6) at 48 h, and -4.9 (-11.4, 1.5) at 72 h.
    2 context sentences
    Summary · context
    Here, we conduct a prospective, randomized, placebo-controlled, blinded study to examine the therapeutic window of Cerebrolysin treatment of rats subjected to embolic stroke.
    Summary · context
    Animals were randomized to receive saline or Cerebrolysin daily for 10 consecutive days starting 4, 24, 48, and 72 h after middle cerebral artery occlusion.
  6. 06AnimalAnimal study (in vivo)Efficacy outcome

    In rats with embolic stroke, the functional-outcome confidence interval for Cerebrolysin initiated at 72 h included zero versus saline.

    In plain wordsIn rats with stroke, Cerebrolysin started at 72 h did not significantly improve function compared with saline.

    Peptide
    Cerebrolysin
    Outcome
    No significant changeFunctional outcome with treatment at 72 h
    Study

    ratn: not reported in source

    Male Wistar rats with embolic middle cerebral artery occlusion
    Comparator
    Saline
    Outcome group
    Exercise and physical function · Nervous system and cognition
    Studied dose
    Dose not stated · 10 consecutive daysAs given in this study (rat).

    Measurements

    Mean difference
    −4.9
    72 h

    Source sentences

    Summary
    Results Cerebrolysin treatment initiated within 48 h after middle cerebral artery occlusion onset significantly improved functional outcome; mean differences and 95% confidence interval were -11.6 (-17.7, -5.4) at 4 h, -7.1 (-13.5, -0.8) at 24 h, -8.4 (-14.2, -8.6) at 48 h, and -4.9 (-11.4, 1.5) at 72 h.
    3 context sentences
    Summary · context
    Global test was employed to assess Cerebrolysin effect on neurological recovery with estimation of mean difference between Cerebrolysin and control-treated groups and its 95% confidence interval in the intent-to-treat population, where a negative value of the mean difference and 95% confidence inter…
    Summary · context
    Here, we conduct a prospective, randomized, placebo-controlled, blinded study to examine the therapeutic window of Cerebrolysin treatment of rats subjected to embolic stroke.
    Summary · context
    Animals were randomized to receive saline or Cerebrolysin daily for 10 consecutive days starting 4, 24, 48, and 72 h after middle cerebral artery occlusion.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    14 Oct 2026, 05:02 UTC

    Study results updated

  2. Version 1

    14 Oct 2026, 01:46 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.